Fusion Antibodies plc
(“Fusion” or the “Company”)
Contract win
Fusion Antibodies plc (AIM: FAB), a specialist in pre-clinical antibody discovery, engineering and supply for therapeutic drug and diagnostic applications, announces the award of a new project covering the transient gene expression (“TGE”) of a client’s lead antibody and a subsequent cryogenic electron microscopy (“CryoEM”) study (the “TGE and CryoEM Project”) under an existing master services agreement with a US-based specialty division of a global pharmaceutical company (the “Client”). The Company has an established relationship with the Client, having recently completed a humanisation project, as announced on 28 August 2025.
Work on the TGE and CryoEM Project is expected to be completed within the current financial year. The contract represents further repeat business from a major pharmaceutical Client and supports Fusion’s strategy to increase its exposure to larger pharmaceutical companies, strengthening the quality and resilience of its revenue base. The technologically complex nature of the contract demonstrates the relevance of the Company’s specialist capabilities and supports its strategy to commercialise technologies such as OptiMAL® and microfluidic cell line development. The TGE and CryoEM Project is expected to generate revenues in excess of £85,000 for the Company.
Adrian Kinkaid, CEO of Fusion, said: “We are delighted to have secured this further project with an established pharmaceutical client, following the successful completion of our recent humanisation programme. This repeat business reflects the strength of our relationship and the value of Fusion's specialist antibody development capabilities. The award also supports our strategy of developing deeper relationships with major pharmaceutical companies, providing opportunities for further collaboration and a more diversified revenue base.
“We look forward to continuing our work together to support the development of therapeutic antibodies. The TGE and CryoEM Project demonstrates Fusion’s experience in delivering high-quality therapeutic antibody services. We are excited to further build on our ongoing relationship with our Client.”
Enquiries:
|
Fusion Antibodies plc |
www.fusionantibodies.com |
|||
|
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR |
|||
|
Fusion Antibodies interactive investor hub |
||||
|
Allenby Capital Limited |
Tel: +44 (0) 20 3328 5656 |
|||
|
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) |
||||
|
Shard Capital Partners LLP |
||||
|
Damon Heath (Joint Broker) |
Tel: +44 (0) 207 186 9952 |
|||
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com |
|||
|
Anna Dunphy |
Mob: +44 (0)7876 741 001 |
|||
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody discovery, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 400 antibodies and successfully completed over 295 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms and antibodies that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.